insitro stock

insitro Stock

HealthTech

Looking to sell insitro stock or options?

Contact us
Founded: 2018Funding to Date: $629M
Visit website

Insitro is a leader in the field of data-driven drug discovery and development, aiming to revolutionize the way drugs are discovered and supplied to patients. By employing machine learning and high-throughput biology, insitro generates vast data sets that tackle major obstacles in pharmaceutical R&D. This enables pharmaceutical companies to utilize predictive models that hasten the process of target selection, therapeutic design and development, and the formulation of clinical strategies.

Investors include:
Andreessen Horowitz logo
Further Key Investors:

Foresite Capital, BlackRock, SoftBank Investment Advisers, HOF Capital, TLI Bedrock, Bezos Expeditions, T. Rowe Price Group, GV, Alexandria Venture Investments, Two Sigma Ventures, A&E Investments, HBM Genomics, Mubadala Capital, Temasek Holdings, Verily Life Sciences, RONA Holdings, Third Rock Ventures, Globalive Capital, WuXi AppTec, ADS Ventures, CPP Investments, Casdin Capital, ARCH Venture Partners.